Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer
Condition(s):Unresectable Metastatic Colorectal CancerLast Updated:March 9, 2022Recruiting
Hide Studies Not Open or Pending
Condition(s):Unresectable Metastatic Colorectal CancerLast Updated:March 9, 2022Recruiting
Condition(s):Relapse/Refractory Multiple MyelomaLast Updated:August 31, 2023Active, not recruiting
Condition(s):Acute Myeloid Leukemia; Myelodysplastic SyndromeLast Updated:June 9, 2020Recruiting
Condition(s):Unresectable Metastatic Colorectal CancerLast Updated:November 20, 2020Recruiting
Condition(s):AML, Adult; Myelodysplastic SyndromesLast Updated:October 29, 2019Withdrawn
Condition(s):AML; MDSLast Updated:May 4, 2021Completed
Condition(s):Colon Cancer Liver MetastasisLast Updated:February 28, 2024Terminated
Condition(s):Colon Cancer Liver MetastasisLast Updated:June 16, 2020Unknown status
Condition(s):Acute Myeloid Leukemia/Myelodysplastic Syndrome; Multiple Myeloma (MM)Last Updated:September 19, 2019Unknown status
Condition(s):Heart FailureLast Updated:July 11, 2016Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.